BHVN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

10.560

Open

10.560

VWAP

10.09

Vol

1.70M

Mkt Cap

1.49B

Low

9.830

Amount

17.10M

EV/EBITDA(TTM)

Total Shares

150.42M

1.41B

EV/OCF(TTM)

P/S(TTM)

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Events Timeline

(ET)

2026-03-19

07:40:00

Biohaven Completes Enrollment in Phase 2 Study of Taldefgrobep Alfa

2026-03-09 (ET)

2026-03-09

12:00:00

Biohaven Shares Volatile, Rise Then Fall to $9.85

2026-03-08 (ET)

2026-03-08

22:30:00

KKR Plans to Sell CoolIT Systems for Over $3B

2026-03-08

17:00:00

Dr. Vinay Prasad to Leave Agency at End of April

News

6.0

04-13Fool

Biohaven Stock Surges 10.14% Following Analyst Buy Rating

2.0

03-24NASDAQ.COM

Biohaven Shares Enter Oversold Territory

8.5

03-23Fool

Sarissa Capital Management Acquires Stake in Biohaven Ltd.

8.5

03-23NASDAQ.COM

Sarissa Capital Management Increases Stake in Biohaven

8.5

03-22NASDAQ.COM

DAFNA Capital Management Increases Biohaven Stake

6.5

03-22Fool

DAFNA Capital Increases Biohaven Stake by 720,000 Shares

13 Analyst Rating

Wall Street analysts forecast BHVN stock price to rise

9 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

11.00

Averages

18.00

High

30.00

Current: 0.000

Low

11.00

Averages

18.00

High

30.00

Canaccord

NULL

Buy

initiated

$21

AI Analysis

2026-04-13

Reason

Canaccord

Price Target

$21

AI Analysis

2026-04-13

initiated

NULL

Buy

Reason

Canaccord initiated coverage of Biohaven with a Buy rating and $21 price target. The company is developing novel therapeutics for immunology, obesity, neuroscience and oncology indications, the analyst tells investors in a research note. The firm views the stock as undervalued on Biohaven's opakalim opportunity alone. It recommends buying the shares into the focal epilepsy readout, which it sees as presenting "significant upside potential."

Citi

Samantha Semenkow

Buy

maintain

$14 -> $17

2026-04-02

Reason

Citi

Samantha Semenkow

Price Target

$14 -> $17

2026-04-02

maintain

Buy

Reason

Citi analyst Samantha Semenkow raised the firm's price target on Biohaven to $17 from $14 and keeps a Buy rating on the shares. The firm sees an attractive risk/reward at current share levels into the company's 2026 catalysts. Citi believes recent competitor data in focal epilepsy are very positive for Biohaven's Phase 3 opakalim trial, which has a readout in the second half of 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BHVN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biohaven Ltd (BHVN.N) is 0.00, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.29

Current PE

0.00

Overvalued PE

-2.61

Undervalued PE

-5.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.48

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.72

Undervalued EV/EBITDA

-6.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

58581.98

Current PS

83.42

Overvalued PS

274098.27

Undervalued PS

-156934.32

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

fast return

Intellectia · 31 candidates

Market Cap: 500.00M - 20.00BBeta: HighRiskIs Optionable: TrueOne Week Predict Return: >= 5.0%

Ticker

Name

Market Cap$

GYRE

Gyre Therapeutics Inc

715.90M

HMY

Harmony Gold Mining Company Ltd

10.67B

DIOD

Diodes Inc

4.03B

NTNX

Nutanix Inc

9.77B

GLUE

Monte Rosa Therapeutics Inc

1.40B

CAR

Avis Budget Group Inc

14.54B

what stock should I buy now to day trade

Intellectia · 96 candidates

Region: USPrice: $5.00 - $80.00Price Change Pct: >= $4.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

MOVE

Corvex, Inc

727.42M

LEG

Leggett & Platt Inc

1.36B

LPTH

LightPath Technologies Inc

740.40M

LNZA

Lanzatech Global Inc

273.92M

LWLG

Lightwave Logic Inc

1.58B

EDSA

Edesa Biotech Inc

49.05M

Should I Buy ppta tomorrow

Intellectia · 77 candidates

Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical ResearchMarket Cap Category: smallWeek Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

CRVS

Corvus Pharmaceuticals Inc

1.65B

RAPT

RAPT Therapeutics Inc

1.60B

ACRS

Aclaris Therapeutics Inc

478.89M

LXRX

Lexicon Pharmaceuticals Inc

566.90M

CTMX

CytomX Therapeutics Inc

896.31M

VOR

Vor Biopharma Inc

700.06M

Whales Holding BHVN

ARS Investment Partners, LLC

Suvretta Capital Management, LLC

TCG Crossover Management, LLC

Kynam Capital Management, LP

Integral Health Asset Management, LLC

Cormorant Asset Management, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biohaven Ltd (BHVN) stock price today?

The current price of BHVN is 9.88 USD — it has decreased -6.08

What is Biohaven Ltd (BHVN)'s business?

What is the price predicton of BHVN Stock?

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is18.00 USD with a low forecast of 11.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biohaven Ltd (BHVN)'s revenue for the last quarter?

Biohaven Ltd revenue for the last quarter amounts to -142.73M USD, decreased -24.85

What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?

Biohaven Ltd. EPS for the last quarter amounts to -130670000.00 USD, decreased -23.49

How many employees does Biohaven Ltd (BHVN). have?

Biohaven Ltd (BHVN) has 274 emplpoyees as of April 26 2026.

What is Biohaven Ltd (BHVN) market cap?

Today BHVN has the market capitalization of 1.49B USD.

BHVN Overview

BHVN Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding BHVN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biohaven Ltd (BHVN) stock price today?

What is Biohaven Ltd (BHVN)'s business?

What is the price predicton of BHVN Stock?

What is Biohaven Ltd (BHVN)'s revenue for the last quarter?

What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?

How many employees does Biohaven Ltd (BHVN). have?

What is Biohaven Ltd (BHVN) market cap?